UroGen Pharma (URGN) Depreciation & Amortization (CF) (2018 - 2026)

UroGen Pharma (URGN) has reported Depreciation & Amortization (CF) for 9 consecutive years, with $100000.0 the latest figure, recorded in Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $375000.0 (up 13.98% YoY) and the FY2025 annual result came in at $307000.0, down 6.69% from the prior year.
• Depreciation & Amortization (CF) climbed to $100000.0 in Q1 2026 per URGN's latest filing, from $75000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for URGN reached as high as $224000.0 in Q4 2022 and fell as low as $29000.0 in Q4 2024.
• A 5-year average of $145470.6 and a median of $123000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) slumped 84.74% — and 2025, when it surged 158.62%.
• Year by year, Depreciation & Amortization (CF) stood at $224000.0 in 2022, then declined by 15.18% to $190000.0 in 2023, then sank by 84.74% to $29000.0 in 2024, then jumped by 158.62% to $75000.0 in 2025, then jumped by 33.33% to $100000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $100000.0, $75000.0, and $100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.